GLP-1 Collective

Policy Tracker · Patient Lens · July 3, 2026

Four lawsuits, one question: why does Ozempic cost so much

Patients and a pharmacy dispute are asking courts to decide whether Novo Nordisk itself is the reason GLP-1 prices stay so high.

4 developments affecting GLP-1 access were tracked on Thursday, July 2, 2026, across 1 category. Each entry links to the full record.

## Courts and enforcement

**[Lawsuit claims Novo Nordisk illegally inflates GLP-1 prices](/lawsuits/cl-73574851)**.

**[Novo Nordisk sued over Ozempic pricing and pharmacy control](/lawsuits/cl-73574829)**.

**[Patient sues Novo Nordisk over GLP-1 pricing and marketing](/lawsuits/cl-73574818)**.

**[Novo Nordisk faces lawsuit over GLP-1 marketing and pricing](/lawsuits/cl-73574670)**.

By Amanda Bonello

Originally published by Patient Lens on GLP-1 Laws, operated by GLP-1 Studio LLC — a for-profit company founded by the Collective's Executive Director. Republished here in full, with permission, at no cost. The Collective pays nothing for it and receives no payment for publishing it. How this works.